TrimRx's Blog
Tirzepatide Fatty Liver — Clinical Evidence & Patient Guide
Tirzepatide demonstrates 59% NASH resolution in clinical trials — how the dual GLP-1/GIP mechanism reduces hepatic steatosis beyond weight loss alone.
Tirzepatide Blood Pressure — Does It Lower or Raise It?
Tirzepatide reduces systolic blood pressure by 5–8 mmHg on average — here’s the mechanism, timeline, and what happens when you stop the medication.
Tirzepatide Inflammation — What Patients Must Know
Tirzepatide reduces systemic inflammation through GLP-1 and GIP receptor activation, improving metabolic markers beyond weight loss alone.
Tirzepatide Cancer Risk — What the Evidence Actually Shows
Tirzepatide carries no elevated cancer risk in human trials. Animal studies found thyroid tumors at extreme doses — context matters. Full evidence
Tirzepatide Sleep Apnea — Does It Help or Worsen OSA?
Tirzepatide reduces obstructive sleep apnea severity through weight loss and direct airway effects — clinical trials show 25–55% reduction in AHI scores
Tirzepatide NAFLD — Clinical Evidence and Patient Outcomes
Tirzepatide demonstrates 59% NASH resolution in clinical trials — significantly outperforming placebo. Evidence, mechanisms, and practical patient
Tirzepatide Black Box Warning — What Patients Must Know
Tirzepatide carries no black box warning. FDA mandates a thyroid tumor risk advisory instead. Here’s the regulatory reality and patient safety profile.
Tirzepatide Thyroid Cancer — Risk, Research & What Patients
Tirzepatide carries a medullary thyroid cancer risk based on rodent studies—here’s what human research shows, who shouldn’t take it, and how to assess
Tirzepatide 5mg — Dosing, Effects & What to Expect
Tirzepatide 5mg is the first maintenance dose after titration, typically reached at week 4. Here’s what happens at this level and what results to expect.
